Paris, France. 19 May 2022. We CARE, a joint initiative of PCR and Stent – Save a Life!, dedicated to restoring faith in cardiovascular healthcare and increasing awareness of the importance of timely and accessible treatment, is presenting a first study at EuroPCR 2022: a UK health economic analysis of the long-term health outcomes and cost for STEMIs during the COVID-19 UK lockdown.

New findings from the Ascension Health System’s internal National Cardiovascular Data Registry (NCDR) analyzing rates of percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) in parallel with COVID-19 surges is being presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. The findings reveal STEMI PCI cases dramatically dropped nearly 30% following the onset of the COVID-19 pandemic and have yet to recover to pre-pandemic levels.

Vaccines may help lessen long covid symptoms in some individuals, say researchers, but more data is needed before any firm conclusions can be drawn

A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.

A consortium led by international scientists from the non-profit, open-science COVID Moonshot has been awarded an initial $68,662,387 from the US National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.

New research finds that the novel coronavirus can make the mouse brain more susceptible to a toxin that induces nerve-cell loss seen in Parkinson’s.

The rollout of remote teaching in New Jersey during the COVID-19 pandemic was haphazard, under-resourced, inequitably delivered, contributed to student and teacher stress and may exacerbate digital and social inequality, according to a Rutgers study.

A study by Japanese researchers showed that getting a mild case of COVID-19 doesn’t translate to lower chances of becoming a long-hauler. And that sex and the presence of long-term symptoms are risk factors for post-COVID psychological distress.

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.